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Activation-induced	 cytidine	 deaminase	 (AID)	 is	 a	 B-cell	 specific	 enzyme	 that	 targets	
immunoglobulin	 (Ig)	 genes	 to	 initiate	 class	 switch	 recombination	 (CSR)	 and	 somatic	
hypermutation	 (SHM)1.	 Through	 off-target	 activity,	 however,	 AID	 has	 a	much	 broader	
impact	on	genomic	instability	by	initiating	oncogenic	chromosomal	translocations	and	
mutations	 involved	 in	 lymphoma	 development	 and	 progression2.	 AID	 expression	 is	
tightly	regulated	in	B	cells	and	its	overexpression	leads	to	enhanced	genomic	instability	
and	lymphoma	formation3.	The	phosphatidylinositol	3-kinase	(PI3K)	δ 	pathway	plays	a	
key	 role	 in	 AID	 regulation	 by	 suppressing	 its	 expression	 in	 B	 cells4.	 	 Novel	 drugs	 for	





to	 the	 Igh	locus	and	 to	several	AID	off-target	sites.	Both	 these	effects	were	completely	
abrogated	in	AID	deficient	B	cells.	PI3Kδ  inhibitors	or	ibrutinib	increased	the	formation	















We	 first	 tested	 the	effects	of	PI3Kδ	 blockade	 in	primary	mouse	B	 cells	 stimulated	with	anti-
CD40	 plus	 IL-4	 to	 undergo	 CSR9.	 In	 these	 cells,	 the	 PI3Kδ	 inhibitor	 idelalisib	 or	 the	 dual	
PI3Kγδ inhibitor	 duvelisib	 accelerated	 and	 increased	 AID	 induction	 whereas	 the	 PI3Kγ	
inhibitor	 AS-604850	 did	 not	 affect	 AID	 abundance	 (Fig.	 1a).	 Consistently,	 AID	mRNA	 levels	
were	significantly	enhanced	by	either	idelalisib	or	duvelisib	(Fig.	1b).	To	more	precisely	define	
transcription	 changes	 of	 AID	 in	 activated	 mouse	 B	 cells	 treated	 with	 PI3Kδ inhibitors,	 we	
performed	GRO-Seq	analysis9.	Of	the	5	enhancers	associated	with	the	Aicda	gene,	we	found	a	
substantial	increase	in	both	sense	and	antisense	transcription	in	the	E4	enhancer	downstream	
of	 the	 TSS	 (Fig.	 1c,d),	 consistent	 with	 the	 pattern	 of	 AID	 expression	 we	 described	 in	 CSR-
activated	 and	 germinal	 center	 (GC)	 B	 cells10.	 As	 a	 result	 of	 the	 enhanced	 AID	 expression,	
idelalisib	and	duvelisib	increased	CSR	to	IgG1	in	vitro	in	activated	B	cells	(Fig.	1e)	as	well	as	in	
vivo	in	GC	B	cells	(Extended	Data	Fig.	1a-c).	The	effects	were	significant	at	doses	ranging	from	
0.1	 µM	 to	 1	 µM,	 which	 encompass	 the	 plasma	 concentration	 of	 these	 drugs	 observed	 in	
patients7,11	 (Fig.	 1e,	 Extended	 Data	 Fig.	 1d-f).	 Idelalisib	 and	 duvelisib	 reduced	 B-cell	
proliferation,	whereas	AS-604850	did	not	(Extended	Data	Fig.	1g),	demonstrating	that	PI3Kδ 	
blockade	enhanced	AID	expression	and	CSR	despite	an	inhibition	of	B-cell	proliferation12.	In	a	
reverse	genetic	experiment,	B	 cells	 expressing	a	PI3Kδ gain-of-function	mutant	 (PI3KδE1021K)	
recently	 discovered	 in	 patients	 with	 immunodeficiency	 and	 impaired	 CSR13,14,	 showed	
decreased	AID	mRNA	and	protein	levels	as	well	as	CSR	(Extended	Data	Fig.	1h-j).		
Because	AID	induces	DNA	damage	and	chromosomal	translocations	at	defined	on-target	(Igh	
locus)	 and	 off-target	 (non-Igh	 locus)	 genomic	 sites1,9,15,	 we	 next	 analyzed	 whether	 the	
enhanced	 AID	 expression	 induced	 by	 PI3Kδ	 blockade	 would	 result	 in	 increased	 genome	
instability.	We	 applied	 high-throughput	 genome-wide	 translocation	 sequencing	 (HTGTS)9	 in	
order	 to	 generate	 genomic	maps	 of	 chromosomal	 translocations	 in	 activated	mouse	 B	 cells	
treated	with	idelalisib	or	duvelisib.	By	this	approach,	we	sequenced	thousands	of	translocation	
junctions	 between	 endogenous	 DSBs	 and	 a	 c-myc	 DSB	 initiated	 by	 the	 I-SceI	 nuclease9	
(Supplementary	Table	1).	Overall,	idelalisib	or	duvelisib	similarly	increased	the	formation	of	
translocation	junctions	between	c-myc	and	AID	on	target	sites	in	the	Igh	locus	or	AID	off-target	
sites	 in	 the	 genome	 (Fig.	 2a-c).	 In	 the	 Igh	 locus,	 translocations	 junctions	 increased	 and	
clustered	in	the		Sµ,	Sγ1	and	Sε	regions	as	previously	described9,15	(Extended	Data	Fig.	2a,b).	
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In	 addition,	 the	 number	 of	 AID	 off-target	 sites	 in	 idelalisib	 or	 duvelisib,	 but	 not	AS-604850,	
treated	B	cells	was	substantially	increased	(Fig.	2c,	 Supplementary	Table	2).	AID	off-target	
sites	 induced	by	PI3Kδ	 blockade	were	widely	dispersed	across	 the	genome	(Extended	Data	
Fig.	2c,d),	were	largely	overlapping	with	AID	off-target	sites	previously	identified	by	HTGTS16,	
TC-Seq	 15,	 AID	 ChIP-Seq	 17	 and	 RPA-ChIP	 18	 (Supplementary	 Table	 2),	 and	 included	Aicda	
itself	as	well	as	several	genes	involved	in	recurrent	translocations	in	human	lymphomas,	such	
as	 Pax5,	 Pim1,	 Bcl6,	 Il21r	 and	 Bcl2l1	 (Extended	 Data	 Fig.	 2c-e).	 The	 median	 fold	 change	
translocation	 frequency	was	 2.0	 and	2.6	 for	AID	on-target	 sites	 and	4.3	 and	4.7	 for	AID	off-
target	sites	for	idelalisib	or	duvelisib,	respectively,	with	95	percentiles	up	to	12.9	and	17.0	fold	
changes	 for	 idelalisib	 or	 duvelisib	 (Fig.	 2d).	 Both	 on-target	 and	 off-target	 translocation	
junctions	were	almost	completely	abrogated	 in	AID-deficient	B	cells	 thus	demonstrating	that	
the	 increased	 genomic	 instability	 induced	 by	 PI3Kδ	 blockade	 was	 AID-dependent	 (Fig.	 2c,	
Extended	 Data	 Fig.	 2).	 Conversely,	 on-target	 and	 off-target	 translocation	 junctions	 were	
significantly	reduced	in	B	cells	expressing	the	PI3KδE1021K	active	mutant	(Extended	Data	Fig.	
3a-c).	As	control,	 translocations	to	sites	generated	by	the	off-target	activity	of	 I-SceI	 that	are	
independent	 of	 AID9	 showed	 no	 changes	 in	 B	 cells	 treated	 with	 idelalisib	 or	 duvelisib	
(Extended	Data	Fig.	3d,e).		
Next,	we	 tested	whether	PI3Kδ	 blockade	would	also	 increase	AID-mediated	SHM.	Treatment	





increased	 both	 AID-dependent	 chromosomal	 translocation	 formation	 and	 SHM	 in	 activated	
mouse	B	cells.		
The	current	consensus	is	that	AID	preferentially	targets	genomic	regions	associated	with	high	
transcriptional	 activity,	 more	 frequently	 embedded	 within	 super-enhancers	 (SEs)10,18.	 SE	
regions	typically	are	associated	with	events	that	direct	AID	binding	and	activity,	such	as	RNA	
polymerase	 II	 (Pol	 II)	 transcriptional	 stalling	 with	 Spt5	 accumulation20,	 foci	 of	 convergent	
transcription	(ConvT)10	and	non-coding	RNA	transcription21.	In	activated	B	cells	treated	with	
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idelalisib	or	duvelisib,	 increased	translocation	 junctions	clustered	1–2	kb	downstream	of	 the	
transcription	start	site	(TSS)	(Fig.	3a),	peaked	around	ConvT	regions	(Fig.	3b)	and	intragenic	
SEs	(Fig.	3c),	and	were	associated	with	AID,	Pol	II	and	Spt5	binding	sites	(Fig.	3d,	Extended	




(Extended	 Data	 Fig.	 4e,	 Supplementary	 Table	 3)	 and	 found	 that	 translocation	 junction	





locus	 in	 GC	 B	 cells	 (Extended	 Data	 Fig.	 5a,b).	 Next,	 we	 investigated	 the	 effects	 of	 PI3Kδ	
blockade	 in	 the	 pristane-induced	 plasma	 cell	 (PC)	 tumor	 model	 where	 tumor	 formation	 is	
driven	 largely	 by	 AID-dependent	 Igh/c-myc	 translocations22.	 In	 this	 model,	 treatment	 with	
idelalisib	 or	 duvelisib	 significantly	 increased	 the	 frequency	 of	 PC	 tumor	 formation	 (Fig.	 3f,	
Extended	 Data	 Fig.	 5c-f).	 Overall,	 these	 data	 indicate	 that	 PI3Kδ	 blockade	 enhances	 AID-
mediated	genomic	instability	and	tumor	formation	in	vivo	in	mice.	
Since	PI3Kδ	 inhibitors	have	been	recently	approved	for	the	treatment	of	B	cell	malignancies,	
we	 next	 investigated	 whether	 PI3Kδ	 blockade	 also	 enhanced	 AID	 expression	 in	 human	
leukemia/lymphoma	 B	 cells.	 Idelalisib	 and	 duvelisib,	 but	 not	 AS-604850,	 blocked	 the	
proliferation	of	CLL	(MEC1),	MCL	(Mino	and	JeKo-1)	or	B	lymphoblastoid	(GM06990)	cell	lines	
(Extended	Data	Fig.	6a),	yet	induced	a	significant	increase	in	AID	mRNA	(Fig.	4a-b,	Extended	




activity	 were	 easily	 identified	 as	 unique	 for	 each	 sgRNA	 sequence	 in	MEC1	 and	 JeKo-1	 cell	
lines,	 and	 were	 excluded	 from	 the	 analysis	 (Extended	 Data	 Fig.	 7c-h).	 HTGTS	 not	 only	
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identified	 the	 IgH	 locus	 as	 a	 target	 for	 recurrent	 translocations	 in	 both	 cell	 lines,	 but	 also	
revealed	 translocations	 to	 recently	 identified	 AID	 off-targets	 in	 CLL	 and	 human	 lymphoma,	
such	as	PIM1,	IRF4,	miR142,	and	CXCR4	23-25.	Remarkably,	translocation	to	IgH	as	well	as	to	AID	
off-targets	 were	 significantly	 increased	 by	 idelalisib	 and	 duvelisib	 treatment	 (Fig.	 4d,	
Extended	 Data	 Fig.	 8a-d,	 Supplementary	 Table	 4)	 whereas	 no	 significant	 changes	 were	
observed	 in	 Cas9	 off-targets	 that	were	 used	 as	 internal	 control	 (Extended	 Data	 Fig.	 7c-h).	
When	we	knocked-out	AID	in	MEC1	cells	by	CRISPR/Cas9,	chromosomal	translocations	to	AID	
on-	and	off-targets	were	completely	abrogated	(Fig.	4d,	Extended	Data	Fig.	8a,b,e).	Thus,	as	
in	mouse	B	 cells	PI3Kδ	 blockade	enhanced	genomic	 instability	by	 increasing	AID	expression	
also	in	malignant	human	B	cells.	
Together	with	 PI3Kδ	 inhibitors,	 drugs	 that	 block	 the	 Bruton	 tyrosine	 kinase	 (BTK)	 activity,	
such	 as	 ibrutinib,	 have	 been	 approved	 for	 the	 treatment	 of	 CLL	 and	 MCL5,26.	 Because	 BTK	
modulates	 PI3K	 signaling27	 as	 shown	 by	 the	 block	 of	 AKT	 phosphorylation	 induced	 by	
ibrutinib	 in	 B	 cells	 (Extended	 Data	 Fig.	 9a,b),	 we	 asked	whether	 also	 AID	 expression	 and	
genomic	 instability	 were	 increased	 by	 ibrutinib.	 In	 CSR-activated	 mouse	 B	 cells,	 ibrutinib	
reduced	 cell	 proliferation,	 yet	 enhanced	 AID	 mRNA	 and	 protein	 levels	 as	 well	 as	 CSR	
(Extended	Data	Fig.	9c-f).	Importantly,	ibrutinib	treatment	increased	translocation	junctions	
to	 Igh	 and	 AID	 off-targets	 similarly	 although	 less	 potently	 than	 PI3Kδ	 inhibitors	 (Extended	
Data	Fig.	2a,e	and	9g,h,	Supplementary	Table	5)	and	increased	the	frequency	of	PC	tumor	
formation	in	pristane-treated	mice	(Extended	Data	Fig.	5).	In	human	B	cells,	ibrutinib	reduced	
cell	 proliferation	 (Extended	 Data	 Fig.	 6a),	 yet	 significantly	 enhanced	 AID	 expression	
(Extended	 Data	 Fig.	 10a,b)	 as	well	 as	 the	 frequency	 of	 translocation	 junctions	 to	 AID	 on-
target	and	off-target	sites	(Extended	Data	Fig.	10c,	Supplementary	Table	4).		
Finally,	we	asked	whether	 evidence	 for	 an	 increased	AID	activity	 could	be	 found	 in	patients	
treated	with	 idelalisib	or	 ibrutinib.	We	 collected	 samples	of	CLL	patients	 treated	 for	 several	
months	with	either	idelalisib	or	ibrutinib	and	analyzed	the	frequency	of	SHM	in	known	AID	off-
target	 genes	 by	 paired	 comparison	 of	 samples	 before	 and	 after	 treatment.	 A	 significant	
increase	of	 SHM	 frequency	was	 found	 in	 the	 regions	downstream	 the	TSS	of	 IRF4	 and	PIM1	
genes	and	 in	 the	PAX5	 enhancer	 region,	 all	known	AID	off-targets24,	 in	patients	 treated	with	
	 7	




First,	 increased	 AID	 levels	 induced	 by	 PI3Kδ	 inhibitors	 could	 facilitate	 secondary	 oncogenic	
mutations	or	translocations	in	normal	or	malignant	B	cells	in	patients.	In	this	context,	ibrutinib	




over	 time	 in	patients	on	 these	drugs	 is	 essential,	particularly	given	 that	 current	 follow-up	 is	
very	 short.	 Furthermore,	 increased	 AID	 expression	 could	 accelerate	 resistance	 to	 targeted	
therapy	through	an	increased	mutational	rate,	as	described	for	targeted	therapies	against	BCR-
ABL30.	Finally,	 this	work	demonstrates	 the	general	principle	 that	drugs	considered	non	DNA	
damaging	may	 actually	 induce	 genomic	 instability,	 and	 represents	 the	 first	 application	 of	 a	
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indicated	 inhibitors	 (1	 µM)	 (n	 =	 3	 biological	 replicates).	 For	 gel	 source	 data,	 see	
Supplementary	 Figure	 1.	 b,	 Aicda	 mRNA	 levels	 were	 analyzed	 by	 qRT-PCR.	 Data	 are	
expressed	 as	mean ± s.d.	 (n	 =	 3	 biological	 replicates).	 .	 **	P	≤	 0.01,	 ***	P	≤	 0.001,	 two-tailed	
Student’s	 t-test	 from	 idelalisib	 or	 duvelisib	 vs	 DMSO-treated	 B	 cells.	 c,	 GRO-Seq	 profiles	 of	
Aicda	gene	in	B	cells	at	48	h	after	activation	(n	=	2	biological	replicates).	Blue	profiles:	sense	
transcription,	 Red	 profiles:	 antisense	 transcription.	 d,	 Quantification	 of	 GRO-Seq	 sense	 and	
antisense	 reads	 per	 kilobase	 per	 million	 mapped	 reads	 (RPKM)	 in	 the	 Aicda	 gene,	 **P	 ≤	
0.01,***P	≤	0.001,	multiple	test	adjusted.	e,	IgG1	CSR	in	activated	B	cells.	Data	are	expressed	as	
mean ± s.d.	 (n	=	3	biological	 replicates).	**	P	≤	0.01,	***	P	≤	0.001,	 two-tailed	Student’s	 t-test	
from	idelalisib	or	duvelisib	vs	DMSO	treated	B	cells	
	
Figure	 2	 |	 PI3Kδ 	 blockade	 increases	 the	 frequency	 of	 genome-wide	 chromosomal	
translocations	 in	 activated	 mouse	 B	 cells.	 a,	 Hierarchical	 clustering	 of	 translocation	
frequency	analysis	of	HTGTS	 libraries	generated	 from	WT	and	AID-/-	B	cells	 treated	with	 the	
indicated	 inhibitors.	 AID	 on-target	 (Igh	 and	 Igk	 loci)	 and	 off-target	 are	 listed	 in	
Supplementary	 Table	 2.	 I-SceI	 off-targets	 are	 listed	 in	 Extended	 Data	 Fig.	 3d.	 b,	 Venn	
diagrams	showing	the	fraction	of	shared	AID	off-targets.	c	Numbers	of	AID	on-target	(Igh	and	




interquartile	 range	 (IQR)	 beyond	 the	 box.	 e,	Mutation	 frequency	 of	 the	 immunoglobulin	 Sµ	
region	in	WT	and	AID-/-	B	cells.	Cumulative	frequency	of	C-to-T	or	G-to-A	transition	mutations	








junctions	 and	 GRO-Seq	 reads	 in	 representative	 gene	 examples.	 Numbers	 of	 translocation	
junctions	 in	 focal	 clusters	 are	 indicated	 in	 bold.	 Corresponding	 PolII,	 AID,	 Spt5	 and	
H3K27Ac/SE	 ChIP-Seq	 profiles	 are	 shown.	 e,	 Fold	 change	 HTGTS	 junctions	 plotted	 against	
GRO-Seq	transcription	levels	of	AID	targets	in	B	cells	treated	with	idelalisib	or	duvelisib	over	
DMSO.	Pearson’s	correlation	coefficient;	P	value	calculated	by	two-tailed	F-test.	f,	Development	





cells.	 a,b	 AICDA	mRNA	 relative	 expression	 in	 the	 human	MEC1	or	Mino	B	 cell	 lines	 treated	
with	 the	 indicated	 inhibitors	 (1	 µM).	 Data	 are	 mean ± s.d.	 (n=3	 technical	 replicates,	 n	 =	 3	
biological	replicates).	**	P	≤	0.01,	***	P	≤	0.001;	two-tailed	Student’s	t-test.	 c,	Western	blot	for	
AID	 protein	 expression	 in	MEC1	 and	Mino	 B	 cell	 lines	 (n	 =	 4	 biological	 replicates).	 For	 gel	
source	 data,	 see	 Supplementary	 Figure	 1.	 d,	 Translocation	 junction	 frequency	 in	 AID	 on-
target	 (D2-21	and	Sµ-J4	 region	 in	 the	 IGH	 locus)	and	AID	off-target	 sites	 in	MEC1	B	cell	 line	




and	PIM1,	and	 the	PAX5	enhancer	region	 in	CLL	patients	 treated	with	 idelalisib	or	 ibrutinib.	
Untreated	CLL	patients	are	used	as	control.	Boxplots	indicate	cumulative	frequencies	of	C-to-T	
or	G-to-A	transition	mutation	in	DNA	samples	collected	before	(pre)	and	after	(post)	treatment	








Idelalisib	 (CAL-101,	 GS-1101;	 PI3Kδ	 inhibitor),	 duvelisib	 (IPI-145,	 INK1197;	
PI3Kγδ	dual	inhibitor),	 AS-604850	 (PI3Kγ	inhibitor	)	 and	 ibrutinib	 (BTK	 inhibitor)	 were	





Wild	 type	 (WT)	mice,	 c-myc25xI-SceI	and	 c-myc25xI-SceI;AID-/-	 in	 the	129S2	mice	background.	All	























DNA	 before	 and	 after	 therapy	 from	 CLL	 patients	 (untreated	 n=8;	 idelalisib	 n=10;	 ibrutinib	
n=10;	total	56	samples)	was	extracted	from	peripheral	blood	samples.	Samples	from	idelalisib	
treated	 patients	were	 collected	 in	 the	 99-224	 CLL	Repository	 approved	 by	 the	Dana-Farber	
Cancer	 Institute	 (DFCI)	 Institutional	 Review	 Board	 (IRB).	 Ibrutinib	 treated	 patients	 were	
enrolled	on	a	phase	2,	open-label,	 single-center,	 investigator-initiated	study	approved	by	 the	
National	Heart,	Lung,	and	Blood	Institutional	Review	Board	at	the	National	Institutes	of	Health	
(registered	 at	www.clinicaltrials.gov	NCT01500733).	 All	 patients	 provided	written	 informed	






MicroBeads	 (Invitrogen)	 as	 previously	 described9.	 Briefly,	 all	 the	 non-B	 cells	were	 depleted	
with	anti-CD43	MicroBeads	combined	with	Dynabeads	Biotin	Binder	(Invitrogen);	naive	B	cells	
were	cultured	at	a	concentration	of	5x105	cells/ml	in	RPMI	medium	supplemented	with	15%	
FBS,	 penicillin-streptomycin	 (100	 units/ml),	 L-Glutamine	 (2	 mM),	 anti-CD40	 (1	 µg/ml,	
eBioscience)	 and	 recombinant	 mouse	 IL-4	 (20	 ng/ml;	 PeproTech).	 The	 purity	 of	 B	 cell	
population	 was	 typically	 96-98%	 in	 all	 experiments,	 as	 documented	 by	 flow	 cytometric	
analysis	 of	B220	expression	 in	 enriched	 cells.	 Cells	were	 collected	 after	4	days	of	 treatment	
with	 inhibitors	 to	 isolate	 genomic	 DNA	 for	 HTGTS	 libraries	 and	 targeted	 re-sequencing	
experiments.	For	RNA	and	protein	extraction	cells	were	collected	at	the	indicated	time	points.	
Class	switch	recombination	(CSR)	was	measured	by	staining	with	PE-labeled	anti-mouse	IgG1	







immunized	 by	 intraperitoneal	 injection	 of	 2x108	 SRBCs	 in	 a	 200	ml	 volume.	 After	 5	 days,	 a	






spleens	 of	 immunized	 mice	 by	 immunomagnetic	 depletion:	 first	 non-B	 cells	 were	 depleted	
with	 anti-CD43	 MicroBeads;	 next	 enriched	 B	 cells	 were	 incubated	 with	 a	 cocktail	 of	
biotinylated	 antibodies	 specific	 for	 CD11c	 (eBiosciences)	 and	 IgD	 (eBiosciences)	 to	 remove	
dendritic	cells	and	mature	naive	B	cells,	respectively,	as	previously	reported32.	Enrichment	of	















embedded	 in	 paraffin.	 Four-µm-thick	 sections	 were	 stained	 with	 hematoxylin	 and	 eosin	 to	
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PCR	 for	 Igh/c-myc	 translocations	was	performed	on	500	ng	of	 genomic	DNA	extracted	 from	
ascites	by	adapting	protocols	previously	described33,34.	Briefly,	we	performed	 two	 rounds	of	














on	 12%	 Mini-PROTEIN	 TGX	 gels	 (BIO-RAD),	 transferred	 on	 nitrocellulose	 membrane	 (GE	
Healthcare),	 blocked	with	5%	Skim	milk	 (BIO-RAD).	 Primary	 antibodies	 for	 immunoblotting	
included:	rat	monoclonal	anti-mouse	AID	(mAID-2	clone,	eBioScience,	CAT	NO	#14-5959-82),	
mouse	monoclonal	 anti-human	 AID	 (ZA001,	 Life	 Technologies,	 CAT	NO	 # 39-2500),	 	rabbit	
monoclonal	anti-PI3K	p110δ		 (Y387,	Abcam,	CAT	NO	#32401),	 rabbit	polyclonal	anti-β−actin	
(Sigma,	 CAT	 NO	 #A2066),	 rabbit	monoclonal	 anti-Phospho-AKT	 (S473)	 (D9E,	 Cell	 Signaling	
Technology,	 CAT	 NO	 #4060),	 rabbit	 monoclonal	 anti-AKT	 (pan)	 (C67E7,	 Cell	 Signaling	
Technology,	CAT	NO	#4691).	Membranes	were	developed	with	ECL	solution	(GE	Healthcare).	

































to	 85%	 of	 transduced	 cells).	 PI3K	 inhibitors	 were	 added	 at	 time	 of	 transduction	 and	 then	
maintained	for	the	whole	duration	of	the	activation.	CSR	was	evaluated	by	staining	with	Cy5-
PE-labeled	anti-mouse	B220	(eBiosciences)	and	PE-labeled	anti-mouse	IgG1	(BD	Biosciences).	






were	 selected	 to	 precede	 a	 5'-NGG	 protospacer-adjacent	motif	 (PAM)	 sequence.	 The	 two	 c-
MYC	sgRNAs	(#1	and	#2)	and	 the	AICDA	sgRNA	were	designed	with	 the	CRISPR	design	 tool	
from	 F.	 Zhang	 laboratory	 (http://crispr.mit.edu/).	 Oligonucleotides	 were	 purchased	 from	
Integrated	 DNA	 technology	 (IDT),	 annealed	 and	 cloned	 into	 the	 BsmbI-BsmBI	 sites	




HEK293FT	 cells	 (Invitrogen)	 were	 maintained	 in	 10%	 FBS-containing	 DMEM.	 To	 generate	
lentiviral	 particles,	 5.5x106	HEK293FT	 cells	were	 plated	 per	 10	 cm	dish.	 The	 following	 day,	
cells	were	transfected	by	calcium	phosphate	transfection	method	with	7.2	μg	of	lentiCRISPR	v2	
plasmid,	 3.6	 μg	 of	 VSVG,	 3.6	 μg	 of	 RSV-REV,	 and	 3.6	 μg	 of	 PMDLg/pPRE.	 The	 media	 was	





4x105	human	 neoplastic	 cells	 were	 plated	 into	 six-well	 plates,	 at	 a	 concentration	 of	 2x105	
cells/ml.	Lentiviral	transduction	was	performed	adding	lentiviral	supernatant,	spinning	for	1.5	
h	at	2,400	r.p.m.	in	the	presence	of	polybrene	(6	µg/ml).	The	viral	supernatant	was	exchanged	
for	 fresh	medium	 8	 h	 later.	 	 PI3K	 inhibitors	were	 added	 8	 h	 before	 the	 infection	 and	 after	
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washing.		After	48	h,	cells	were	selected	with	0.2	µg/ml	of	puromycin	to	enrich	for	transduced	




To	generate	 the	AID	knock-out	 (KO)	MEC-1	 cell	 line,	MEC-1	 cells	were	 transduced	with	AID	
CRISPR/Cas9	 lentivirus	 according	 to	 the	 protocol	 described	 above.	 After	 48	hours	 from	
transduction	 cells	were	 selected	with	0.2	μg/ml	of	puromycin	 for	3	days.	 	The	 selected	 cells	
were	seeded	as	single	colonies	in	96-well	plates	by	serial	dilutions.	After	3-4	weeks	of	culture,	





listed	 in	 Supplementary	 Table	 7),	 and	 products	 were	 purified	 using	 PCR	 purification	 kit	
(QIAGEN)	 following	 the	manufacturer’s	 protocol.	 400	 ng	 total	 of	 the	 purified	 PCR	 products	
were	mixed	with	2	μl	10X	Taq	DNA	Polymerase	PCR	buffer	(Life	Technologies)	and	ultrapure	
water	 to	 a	 final	 volume	 of	 20	 μl,	 and	 subjected	 to	 a	 re-annealing	 process	 to	 enable	
heteroduplex	 formation:	95°C	 for	10	min,	95°C	to	85°C	ramping	at	 -2°C	/s,	85°C	to	25°C	at	 -
0.25°C	/s,	and	25°C	hold	for	1	min.	After	re-annealing,	products	were	treated	with	SURVEYOR	





intensity	 of	 the	 undigested	 PCR	 product,	 and	 b	 and	 c	 are	 the	 integrated	 intensities	 of	 each	
cleavage	products.	
	




containing	 10	 μg/ml	 Proteinase	 K	 and	 incubation	 at	 56°C	 overnight,	 followed	 by	 standard	
isopropanol	extraction,	wash	in	ethanol	70%	and	resuspension	in	TE	buffer.	HTGTS	libraries	
were	 generated	 by	 emulsion-mediated	 PCR	 (EM–PCR)	methods	 as	 previously	 described9.	 In	
brief,	 genomic	 DNA	 was	 digested	 overnight	 with	 HaeIII	 frequent	 cutter	 enzyme.	 HaeIII-
generated	 blunt	 ends	 were	 A-tailed	 with	 Klenow	 polymerase	 (3'-5'	 exo-;	 New	 England	





were	 performed	 in	 the	 following	 conditions:	 98ºC	 for	 10	 seconds,	 58ºC	 for	 30	 seconds,	 and	
72ºC	 for	 30	 seconds.	 Multiple	 reactions	 were	 performed	 in	 generating	 large-scale	 libraries.	
Biotinylated	 PCR	 products	 were	 isolated	 using	 the	 Dynabeads	 MyOne	 Streptavidin	 C1	 kit	
(Invitrogen),	 followed	 by	 an	 additional	 2	 hour-digestion	 with	 blocking	 enzymes	 was	
performed.	PCR	products	were	eluted	from	the	beads	via	a	30	minutes	 incubation	at	65°C	in	
95%	 formamide/10	mM	EDTA	and	purified.	The	purified	products	were	 then	amplified	 in	 a	
second	 round	with	 em-PCR	 in	 an	 oil-surfactant	mixture.	 The	 emulsion	mixture	was	 divided	
into	 individual	 aliquots	and	PCR	was	performed	using	 the	 following	 conditions:	20	 cycles	of	
94°C	for	30	seconds,	60°C	for	30	seconds,	and	72°C	for	1	minute.	Following	PCR,	the	products	
were	 pooled	 and	 centrifuged	 in	 a	 table-top	 centrifuge	 for	 5	 minutes	 at	 14,000	 r.p.m.	 to	
separate	the	phases	and	the	oil	layer	was	removed.	The	sample	was	then	extracted	three	times	
with	diethyl	ether	and	DNA	was	re-purified.	The	third,	non-emulsion,	round	of	PCR	(10	cycles)	
was	 performed	 with	 the	 same	 primers	 as	 in	 round	 2,	 but	 with	 the	 addition	 of	 linkers	 and	
barcodes	 for	 Illumina	 MiSeq	 sequencing.	 PCR	 products	 were	 size-fractionated	 for	 DNA	
fragments	between	300	and	800	base	pairs	on	a	1%	agarose	gel,	 column	purified	 (QIAGEN)	
before	loading	onto	Illumina	Miseq	machine	for	sequencing.	
Nucleotide	 sequences	 of	 junctions	 were	 generated	 by	 Mi-Seq	 (Illumina	 NS500	 SE150)	
sequencing	 at	 the	 Molecular	 Biology	 Core	Facilities	 of	 the	 Dana-Farber	 Cancer	 Institute.	 At	
least	 three	 independent	 libraries	 were	 generated	 and	 analyzed	 for	 each	 experimental	
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demultiplexed	 by	 designed	 barcode,	 and	 then	 filtered	 by	 the	 presence	 of	 the	 primer	 plus	
additional	 5	 downstream	 bases	 as	 bait	 portion.	 Barcodes	 and	 primers	 used	 are	 listed	 in	
Supplementary	Table	1	and	7.	Lastly,	the	barcode,	primer	and	bait	portion	of	the	remained	
sequences	were	masked	for	alignment	analysis.		
Alignment	 and	 Filtering.	 The	 sequences	 for	 each	 experiment	 were	 aligned	 and	 filtered	 as	
previously	 described9.	 Briefly,	 we	 aligned	 sequences	 to	 the	 mouse	 reference	 genome	
(GRCm37/mm9)	 or	 human	 genome	 (GRCh38/hg38)	 using	 BLAT,	 and	 then	 filtered	 artificial	
junctions	 by	 removing	 PCR	 repeats	 (reads	 with	 same	 junction	 position	 in	 alignment	 to	 the	
reference	 genome	 and	 a	 start	 position	 in	 the	 read	 less	 than	 3	 bp	 apart),	 invalid	 alignments	
(including	alignment	scores	<	30,	reads	with	multiple	alignments	having	a	score	difference	<	4	
and	alignments	having	10-nucleotide	gaps)	and	ligation	artifacts	(for	example,	random	HaeIII	
restriction	 sites	 ligated	 to	 bait	 breaksite).	 Translocation	 junction	 position	 was	 determined	
based	on	the	genomic	position	of	the	5’	end	of	the	aligned	read.	
Hotspot	 Identification.	 Translocation	 junctions	 data	 from	 similar	 size	 biological	 replicates	
were	pooled	 for	hotspots	 identification.	First, we	employed	SICER	1.136	 to	 identify	candidate	
regions	where	HTGTS	junctions	were	significantly	enriched	against	genome-wide	background.	
The	 parameters	 used	 were	 as	 follows:	 window	 size,	 1000;	 gap	 size,	 2000;	 e,	 0.000001;	
redundancy,	 1;	 effective	 genome	 fraction,	 0.77	 for	 mouse	 or	 0.74	 for	 human.	 Next,	 we	
eliminated	from	analysis	the	following	hotspots:	(1)	hotspots	in	the	region	+	4Mb	around	Myc	
bait	 breaksite	 including	 the	 Pvt1	 gene	 as	 previously	 described9;	 (2)	 hotspots	 with	
junctions	number	 less	 than	5;	 (3)	 hotspots	with	 strand	 bias.	We	 used	 the	 following	 entropy	
formula	to	measure	strand	bias	as	S=-P×log2(P)-(1-P)×log2(1-P),	where	P	is	the	percentage	of	
junctions	from	the	plus	stand,	and	1-P	is	the	percentage	of	junctions	from	the	minus	strand.	If	








partially	 overlapped	 were	 merged	 to	 define	 common	 hotspot	 regions	 that	 were	 used	 as	
reference	to	compare	junction	frequency	between	different	experiments.	
	
Junction	 frequency	 calculation	 and	 representation.	 Translocation	 junction	 frequencies	 in	
hotspots	were	normalized	to	reads	per	million	(RPM).	In	boxplot	for	fold-change	comparison,	
to	avoid	"division	by	zero"	error,	0	was	replaced	with	1,	and	then	normalized	to	corresponding	
RPM	 in	 library.	 For	 clustering	 heatmap,	 the	RPM	was	 transformed	 in	 a	 log2	 value,	 and	 then	
median	centered.	The	genome-wide	 translocation	circle	plots	were	made	using	Circos	 tool38.	
Translocation	 junction	 distributions	 were	 visualized	 by	 IGV	 2.3.639.	 For	 translocation	







Statistical	 comparison	 of	 junction	 frequency	 in	 hotspots.	 Statistical	 significance	 of	
differential	 junction	 frequency	 in	 hotspots	 were	 performed	 using	 SICER	 1.136	 with	 the	





PI3K	 inhibitors,	 as	 previously	 described9.	 GRO-Seq	 libraries	 were	 sequenced	 on	 the	 Hi-Seq	
2000	platform	with	single-end	reads	and	analyzed	as	follows:	GRO-seq	data	were	aligned	using	
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Bowtie	 software40	 mouse	 reference	 genome	 (GRCm37/mm9).	 Uniquely	 mapped,	
nonredundant	sequence	reads	were	retained.	Next,	we	used	HOMER	software	to	count	reads	
and	 calculate	 the	 nascent	 RNA	 expression	 levels	 as	 RPKM	 (reads	 per	 1000bp	 per	 million	
mapped	 reads)	 in	whole	 genes	 or	 in	 focal	 translocation	 clusters,	 and	 to	 identify	 transcripts	
from	both	 strands	of	 chromosomes41.	The	ConvT	 region	was	defined	as	 sense	and	antisense	
transcription	 overlaps	 that	 were	 longer	 than	 100	 bp10.	 Statistical	 analysis	 for	 differential	
expression	and	log	fold-change	calculation	were	performed	using	DESeq242	in	whole	genes	or	




Phusion	 High	 Fidelity	 DNA	 polymerase	 (Thermo-Scientific)	 was	 used	 to	 amplify	 selected	
regions	 from	 template	 genomic	 DNA.	 Oligonucleotide	 primers	 are	 listed	 in	 Supplementary	
Table	 7:	 amplification	 conditions	 for	 each	 gene	 are	 available	 on	 request.	 Amplification	
products	were	purified	using	PCR	purification	kit	(QIAGEN)	and	GEL	extraction	kit	(QIAGEN)	
following	 the	 manufacturer’s	 protocol	 and	 sequenced	 bi-directionally	 in	 a	 Mi-Seq	 (Illumina	






score	<	20	and	 length	<	50	were	removed.	Samples	with	 less	 than	100	reads	were	excluded	
from	 analysis.	 The	 remained	 sequences	 were	 used	 to	 calculate	 mutation	 rate.	 Sequences	
obtained	 from	 each	 designed	 region	were	 aligned	 to	 the	 reference	 sequence	 using	 BLASTN	
with	 alignment	 length	 >	 200.	 Mutations	 were	 calculated	 after	 filtering	 steps,	 as	 previously	
described43.	 Briefly,	 mutations	 first	 had	 to	 pass	 a	 Neighbourhood	 Quality	 Standard	 (NQS)	
criteria	 requiring	 a	minimum	 Phred	 score	 of	 30	 for	 the	mutation	 itself,	 and	 20	 for	 the	 five	
adjacent	 bases	 on	 either	 side.	 Mutations	 that	 were	 within	 five	 bases	 of	 more	 than	 two	
additional	 mutations	 were	 excluded.	 Mutations	 within	 two	 bases	 of	 a	 deletion	 or	 insertion	
were	also	excluded.	In	addition,	bases	with	mutation	rate	>	0.01	were	excluded	as	a	result	of	
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two-tailed	 Student’s	 t-test.	 h,	 Representative	 western	 blot	 for	 AID	 and	 PI3K	 p110δ	 protein	
expression	 in	 mouse	 B	 cells	 transduced	 with	 retrovirus	 expressing	 PI3K	 p110δWT	 or	 the	
p110δE1021K	active	mutant	(n	=	4	biological	replicates).	i,	Aicda	mRNA	levels	analyzed	by	qRT-
PCR	in	activated	B	cells	transduced	with	PI3K	p110δWT	or	the	p110δE1021K	active	mutant.	Data	











as	 indicated	 in	 the	Methods.	 **	FDR	≤	0.01,	 ***	FDR	≤	0.001,	 ****	FDR	≤	1x10-10.	 	b,	Detailed	
view	of	the	distribution	of	translocation	junctions	in	the	Igh	locus	from	WT	and	AID-/-	mouse	B	
cells	treated	with	the	indicated	inhibitors.	Numbers	of	translocation	junctions	in	focal	clusters	
are	 indicated	 in	bold.	c,	Histograms	 showing	 the	AID	off-targets	with	 significantly	 increased	
frequency	of	HTGTS	 junctions	(FDR	<	0.001)	 induced	by	 idelalisib	 treatment	as	compared	 to	
DMSO	(54	out	of	59	off-target	sites,	91.5%)	in	WT	and	AID-/-	activated	B	cells	.	Significance	is	
calculated	 as	 indicated	 in	 the	 Methods.	 Circos	 plots	 show	 the	 overview	 of	 genome-wide	
translocation	 distribution.	 Individual	 translocations	 from	 c-myc	 to	 AID	 target	 sites	 are	
represented	as	arcs	originating	from	c-myc	DSB	breaks	on	chromosome	15.	Thickness	and	red	
color	intensity	of	the	arcs	represent	the	fold	increase	of	translocation	frequency	in	idelalisib	vs	
DMSO	 treated	 cells.	 d,	 Histograms	 showing	 the	 AID	 off-targets	 with	 significantly	 increased	
frequency	 of	 translocation	 junctions	 (FDR	 <	 0.001)	 induced	 by	 duvelisib	 treatment	 as	
compared	 to	DMSO	 (55	out	 of	 63	off-target	 sites,	 87.3%)	 in	WT	and	AID-/-	 activated	B	 cells.	
Significance	 is	 calculated	 as	 indicated	 in	 the	 Methods.	 Circos	 plots	 show	 the	 overview	 of	
genome-wide	translocation	distribution.	e,	Translocation	junction	distribution	(top),	GRO-Seq	
(middle)	 and	ChIP-Seq	 (bottom)	profiles	 in	 three	 representative	AID	 off-target	 genes	 (Pim1,	
Cd83,	Bcl6)	 in	WT	 and	 AID-/-	 activated	 B	 cells	 treated	with	 idelalisib,	 duvelisib	 or	 ibrutinib.	
GRO-Seq	sense	and	antisense	 transcription	 is	displayed	 in	blue	and	red	profiles.	Numbers	of	
translocation	junctions	in	focal	clusters	are	indicated	in	bold.	
	
Extended	 Data	 Figure	 3	 |	 Frequency	 of	 AID	 on-target	 and	 off-target	 translocation	
junctions	 is	 reduced	 in	 activated	mouse	B	 cells	 transduced	with	 the	PI3K	p110δE1021K	
active	 mutant.	 a,	 Histograms	 showing	 junction	 frequency	 in	 activated	 mouse	 B	 cells	
transduced	 with	 retrovirus	 expressing	 PI3K	 p110δWT	 or	 the	 p110δE1021K	 active	 mutant.	
Significance	is	calculated	as	FDR	by	comparing	PI3K	p110δWT	to	p110δE1021K	transduced	B	cells	
as	indicated	in	the	Methods.	**	FDR	≤	0.01,	***	FDR	≤	0.001.	b	Detailed	view	of	the	distribution	
of	 translocation	 junctions	 in	one	representative	 I-Scel	off-target	(Fermt2).	c,	Detailed	view	of	
the	distribution	of	translocation	junctions	in	the	Igh	locus.	Numbers	of	translocation	junctions	
in	 focal	 clusters	 are	 indicated	 in	 bold.	 d,	 Histograms	 showing	 frequency	 of	 translocation	
junctions	 as	 RPM	 for	 I-Scel	 off-targets	 in	 WT	 and	 AID-/-	 activated	 B	 cells	 treated	 with	 the	
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Extended	 Data	 Figure	 4	 |	 PI3Kδ 	 blockade	 increases	 somatic	 hypermutation	 (SHM)	
frequency	in	Igh	V	region	in	activated	mouse	B	cells	and	transcription	of	genes.	a,	Map	of	
mutations	 on	 the	 VB1-8	 productive	 allele	 sequence	 in	 activated	 B	 cells	 treated	 with	 the	
indicated	 inhibitors.	 The	 y-axis	 indicates	 the	 mutation	 frequency	 at	 each	 nucleotide	 in	
sequences	that	have	0	to	2	mutations	per	sequence	at	day	4	of	stimulation	after	subtraction	of	
mutation	 frequency	 at	 day	 0	 of	 stimulation.	 Green	 shading	 indicates	 top	 s.e.m.	 from	 three	
independent	mice.	Orange	and	yellow	bars	mark	the	positions	of	AGCT	and	other	RGYW	motif	
that	is	not	AGCT,	respectively.	One	experiment	is	represented	out	of	three	biological	replicates	
with	 similar	 results.	 b,	Mutation	 frequency	of	nucleotide	454	 (top)	 and	455	 (bottom)	of	 the	
VB1-8	 productive	 allele	 at	 day	 4	 after	 subtraction	 of	 mutation	 frequency	 at	 day	 0.	 Data	
represent	 mean	 of	 three	 independent	 stimulations	 of	 B	 cells	 from	 three	 independent	 mice.	
Error	bars	 indicate	s.d.	Fold	changes	between	each	mean	are	 indicated.	 c,	Stacking	bar	chart	
shows	 percentage	 of	 sequences	 that	 have	 the	 indicated	 number	 of	mutations	 per	 sequence.	
Data	are	displayed	as	 the	mean	 from	three	 independent	stimulations	of	B	cells	derived	 from	
three	mice.	Error	bars	indicate	s.e.m.		d,	The	number	of	reads	from	individual	mice	for	the	data	
are	shown	in	(a).	 	e,	MA	plots	of	 log	fold-changes	generated	by	DESeq2	in	R	package	against	





Extended	Data	Figure	5	 |	PI3Kδ 	 inhibitors	and	ibrutinib	 increase	c-myc	DSB	formation	
and	the	incidence	of	plasma	cell	(PC)	tumor	in	mice.	a,	Detailed	view	of	the	distribution	of	
rearrangements	(deletions	or	inversions)	in	the	c-myc	locus	in	mice	treated	as	above.	Numbers	






the	 experimental	 outline	 of	 pristane-induced	PCT	 in	mice	 treated	with	PI3Kδ	 inhibitors	 and	
ibrutinib.	The	mice	were	treated	 in	two	independent	biological	experimental	replicates,	each	
consisting	of	6	mice	per	group.	d,	Direct	PCR	assay	for	Igh/c-myc	translocation	in	mice	with	PC	
tumors.	Translocations	 from	c-myc	 to	 the	 IgHα	 locus	are	shown.	Translocations	 for	 the	only	
mouse	 in	 the	 vehicle	 group	 and	 from	 three	 example	 mice	 from	 treated	 groups	 are	 shown.	
Bands	 were	 purified	 from	 gels	 and	 were	 sequenced	 to	 confirm	 the	 Igh/c-myc	 translocation	
junction.	 For	 gel	 source	data,	 see	Supplementary	 Figure	 1.	e,	Development	of	PC	 tumor	 in	
mice	 induced	with	pristane	and	 treated	with	 idelalisib,	duvelisib	or	 ibrutinib	 is	plotted	over	
time.	The	presence	of	PC	tumors	was	confirmed	by	histology	(n	=	12	for	each	treatment	in	2	
independent	cohorts	of	6	mice).	P	values	calculated	by	Log-rank	(Mantel-Cox)	test.		f,	Example	





a,	Viable	cells	were	counted	at	 the	 indicated	 time	points	by	Trypan	Blue	exclusion	 in	MEC1,	
Mino,	 JeKo-1	 and	GM06990	 cell	 lines	 treated	with	 the	 indicated	 inhibitors	 (1	µM).	Data	 are	
expressed	as	mean ± s.d.	(n=3).	P	values	calculated	by	two-tailed	Student’s	t-test.	b,	Histograms	
showing	the	AICDA	mRNA	relative	expression	in	JeKo-1	and	GM06990	cell	lines	treated	with	1	
µM	 inhibitors.	Data	 are	 expressed	 as	mean ± s.d.	 (n	 =	 3	 technical	 replicates,	 n	 =	 3	 biological	
replicates).	*	P	<	0.05,	**	P	≤	0.01,	***	P	≤	0.001,	two-tailed	Student’s	t-test.	c,	Western	blot	for	
AID	protein	expression	 in	MEC1	and	Mino	B	 cell	 lines	 treated	with	0.1	µM	 inhibitors	 (n	=	2	
biological	replicates).	d,	Western	blot	for	AID	protein	expression	in	JeKo-1	and	GM06990	B	cell	
lines	 treated	 with	 1	 µM	 inhibitors	 (n	 =	 4	 biological	 replicates).	 For	 gel	 source	 data,	 see	
Supplementary	 Figure	 1.	e,	Histograms	showing	 the	AID	protein	 relative	expression	at	 the	
indicated	 time	 points	 in	 MEC1,	 Mino,	 JeKo-1	 and	 GM06990	 cell	 lines	 treated	 with	 1	 µM	
inhibitors.	AID	abundance	was	measured	by	 ImageJ	 software	and	normalized	 for	 the	β-actin	
	 30	








sequence	 is	 in	 red.	 b,	 Surveyor	 Assay	 to	 measure	 the	 cutting	 efficiency	 of	 the	 c-MYC	 gene	
targeted	 in	 JeKo-1	 cell	 line.	 Locus	 modification	 efficiencies	 are	 analyzed	 5	 days	 after	
transduction	of	c-MYC-#1	or	c-MYC-#2	Cas9	lentivirus.	Estimated	indel	formation	is	indicated	











each	 treatment,	 data	 are	 from	 pooled	 HTGTS	 libraries	 of	 similar	 size	 as	 indicated	 in	
Supplementary	 Table	 1	 g,h,	 Detailed	 view	 of	 the	 distribution	 of	 translocation	 junctions	 in	
representative	 Cas9	 off-target	 sites	 for	 c-MYC-#1	 (g)	 or	 c-MYC-#2	 (h).	 	 Numbers	 of	
translocation	junctions	in	focal	clusters	are	indicated	in	bold.	
	
Extended	Data	Fig	8	 |	Translocations	 to	AID	off-targets	are	 increased	by	 idelalisib	and	
duvelisib	treatment	in	MEC1	and	JeKo-1	cell	line.	Distribution	of	translocation	junctions	in	
the	 IgH	 locus	 (a)	 and	 in	 the	 IRF4	 AID	off-target	 gene	 (b)	 in	MEC1	 cells.	AID	knock-out	 (KO)	




µM).	Data	are	 from	pooled	HTGTS	 libraries	of	similar	size	 (Supplementary	Table	 1	 and	 4)	
from	3	independent	experiments.	Statistical	analysis	in	Methods.	*	FDR	≤	0.1,	**	FDR	≤	0.01.		d,	
Distribution	 of	 translocation	 junctions	 in	 the	PIM1	 AID	 off-target	 gene	 in	 JeKo-1	 B	 cell	 line.	




AID	 KO	 clone	 #4	 was	 treated	 with	 1	µM	DMSO,	 idelalisib	 or	 duvelisib	 (right	 panel)	 (n	 =	 2	
biological	replicates).	For	gel	source	data,	see	Supplementary	Figure	1.	
	
Extended	 Data	 Fig	 9	 |	 Ibrutinib	 increases	 AID	 expression	 and	 the	 frequency	 of	
translocations	 to	 AID	 on-	 and	 off-target	 sites	 in	 mouse	 activated	 B	 cells	 a,	 AKT	
phosphorylation	was	detected	by	Western	Blot	in	mouse	activated	B	cells	treated	with	DMSO,	
idelalisib,	 duvelisib	 or	 ibrutinib	 (1	 µM)	 for	 the	 indicated	 time	 points	 (n	 =	 2	 biological	
replicates).	 For	 gel	 source	 data,	 see	 Supplementary	 Figure	 1.	 b,	 MEC1	 and	 Mino	 human	
lymphoma	cells	were	 treated	with	 the	 indicated	 inhibitors	 (1	µM)	and	AKT	phosphorylation	
was	evaluated	by	Western	Blot	(n	=	3	biological	replicates).	c,	Viable	cells	were	counted	at	the	
indicated	 time	 points	 by	 Trypan	 Blue	 exclusion	 in	 activated	 B	 cells	 treated	 with	 DMSO	 or	
ibrutinib	 (1	µM).	 Data	 are	 expressed	 as	mean ± s.d.	 (n=3).	P	 values	 calculated	 by	 two-tailed	
Student’s	t-test.	d,	Western	blot	for	AID	protein	expression	in	activated	B	cells	treated	with	1	
µM	 ibrutinib.	 The	 DMSO	 panel	 from	 Fig.	 1a	 is	 shown	 for	 comparison	 (n=3	 biological	
replicates).	e,	Aicda	mRNA	levels	analyzed	by	qRT-PCR	in	activated	B	cells	treated	with	DMSO	
or	 ibrutinib	 (1	 µM).	 Data	 are	 expressed	 as	 mean ± s.d.	 (n	 =	 3	 technical	 replicates,	 n	 =	 3	




B	 cells	 treated	 with	 ibrutinib.	 Targets	 are	 divided	 based	 on	 the	 statistical	 significance	 of	
	 32	
increased	 junctions	 frequency	compared	to	DMSO	treatment	(FDR	<	0.001	on	the	 left;	FDR	<	
0.01	on	the	right).	Statistical	analysis	is	indicated	in	the	Method.	For	each	treatment,	data	are	




Extended	 Data	 Fig	 10	 |	 Ibrutinib	 increases	 AID	 expression	 and	 the	 frequency	 of	
translocations	 to	 AID	 on-	 and	 off-target	 sites	 in	 human	 B	 cells.	 a,	AICDA	 mRNA	 levels	
analyzed	 by	 qRT-PCR	 in	 MEC1,	 Mino,	 JeKo-1	 and	 GM06990	 cell	 lines	 after	 treatment	 with	
DMSO	or	ibrutinib.	Data	are	expressed	as	mean ± s.d.	(n	=	3	technical	replicates,	n	=	3	biological	
replicates).	*	P	<	0.05,	**	P	≤	0.01,	***	P	≤	0.001,	two-tailed	Student’s	t-test.	b,	Western	blot	for	
AID	 protein	 expression	 in	 MEC1,	 Mino,	 JeKo-1	 and	 GM06990	 B	 cell	 lines	 treated	 with	 the	
indicated	inhibitors	(1	µM)	for	48	h.	For	comparison,	Mino	and	GM06990	panels	correspond	to	





and	 4).	 Significance	 is	 calculated	 as	 FDR	 in	 ibrutinib	 over	 DMSO	 treated	 human	 B	 cells.	
Statistical	analysis	is	indicated	in	the	Method.	***	FDR	≤	0.001.	d,	Mutation	frequency	of	control	
non	AID	off-targets:	 intragenic	regions	for	PAX5,	MTFR1,	BCAT1,	CLMN,	UBXN7,	ERICH6B,	and	
random	 intergenic	 regions	on	Chr.	1,	Chr.	8,	 and	Chr.	18	were	 targeted	 re-sequenced	 in	CLL	
patients	 untreated	 or	 treated	 with	 idelalisib	 and	 ibrutinib.	 Boxplots	 indicate	 cumulative	
frequencies	of	C-to-T	or	G-to-A	transition	mutation	in	DNA	samples	collected	before	(pre)	and	
after	 (post)	 treatment	 in	 each	 patient	 (control	 n=8,	 idelalisib	 n=10,	 ibrutinib	 n=10,	
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